Umbilical cord tissue product for joint, tendon, ligament and spine conditions
Tests an umbilical allograft for pain and function in adults with musculoskeletal conditions.
Key facts
- Who runs it
- R3 Stem Cell
- Where
- Encino, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal Conditions
- Status
- Not yet recruiting
- People taking part
- 200 people, planned
- Started
- 1 Jan 2022
- Expected to end
- 1 Jan 2030
- Type of study
- Interventional
- Treatments tested
- Umbilical Allograft
- Record updated
- 17 September 2021
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a muscle, joint, tendon, ligament or other musculoskeletal condition. They get an umbilical cord tissue product to see if it eases pain and improves function.
- Age
- 18 years and over.
- Sex
- All sexes can join.
- Disease stage
- Any type of musculoskeletal condition, such as osteoarthritis, tendinitis, sports injury, degenerative disc disease, ligament injury, neuropathy or pelvic pain.
Main reasons for not taking part
- Active infection
- Pregnancy
- Breastfeeding
- Clotting (blood clotting) disorder
- Not able to attend follow-up visits or answer follow-up by phone or email
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age 18 and over
- Ability to attend follow up visits or at least converse on phone or complete email follow up forms
- Competent to understand the study protocol and provide voluntary informed consent
Who cannot take part
- Active Infection
- Clotting disorder
- Pregnancy, Lactating
Where in United States
- Advanced Stem Cell InstituteEncino, United StatesContact: David Greene, PhDNot yet recruiting
About the trial
What the trial wants to find out
The aim of the study is to determine the efficacy of an Amniotic Fluid Tissue Product for pain relief and functional improvements for all types of musculoskeletal conditions. The study is prospective, with outcome measures being obtained at numerous time points after the regenerative procedure.
The group in the trial
- Umbilical AllograftTreatment being tested
The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the product utilized will be either 1.0cc's or 2cc's.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of Regenerative Medicine Outcomes With Umbilical Allograft for Musculoskeletal Conditions
- Plain-language title
- Umbilical cord tissue product for joint, tendon, ligament and spine conditionsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 17 September 2021